Table 3.
Clinical experience with histone deacetylase inhibitors and their combinations.
| Study | Phase | n | Major toxicity | Overall response rate (%) | Ref. |
|---|---|---|---|---|---|
| MS-275 | I | 39 | Neuro | 0 | [66] |
| Depsipeptide | I | 10 | Constitutonal | 0 | [62] |
| Vorinostat | I | 41 | GI | 17 | [67] |
| MGCD0103 | I | 29 | GI | 10 | [64] |
| LBH589 | I | 29 | Cardiac | 0 | [65] |
| VPA | II | 75 | Neuro | 24 | [70] |
| AZA + PB | I | 36 | Neuro | 30 | [75] |
| DAC + VPA | I/II | 54 | Neuro | 22 | [76] |
| AZA + VPA | I/II | 53 | Neuro | 42 | [77] |
| AZA + MGCD0103 | I/II | 52 | GI | 36 | [78] |
AZA: 5-azacytidine; DAC: Decitabine; GI: Gastrointestinal; Neuro: Neurotoxicity; PB: Phenylbutyrate; VPA: Valproic acid.